Publicaciones › Retinopatía diabética: clínica, función y progresión
Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study
Agonistas del receptor de péptido similar al glucagón 1, retinopatía diabética y angiogénesis: El estudio AngioSafe de diabetes tipo 2
| Año | 2019 |
|---|---|
| Fuente | The Journal of clinical endocrinology and metabolism |
| Tipo | article · Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't |
| Autores (30) | Bénédicte Gaborit, Jean-Baptiste Julla, Samaher Besbes, Matthieu Proust, Clara Vincentelli, Benjamin Alos, Patricia Ancel, Fawaz Alzaid, Rodrigue Garcia, Philippe Mailly, Florence Sabatier, Maud Righini, Pierre Gascon, Frédéric Matonti, Marie Houssays, Louisa Goumidi, Lucile Vignaud, Xavier Guillonneau, Ali Erginay, Bénédicte Dupas, Jennifer Marie-Louise, Marianne Autié, Tiphaine Vidal-Trecan, Jean-Pierre Riveline, Nicolas Venteclef, Pascale Massin, Laurent Muller, Anne Dutour, Jean-François Gautier, Stéphane Germain |
| Posición de Erginay | 19 de 30 |
| Citas | 99 (OpenAlex) |
| Enlaces | DOI 10.1210/clinem/dgz069 · PubMed 31589290 · OpenAlex · Texto completo en acceso abierto |
| Líneas | Enfermedades vasculares, genéticas e inflamatorias de la retina Retinopatía diabética: clínica, función y progresión Imagen retiniana: OCT, OCT-angiografía y ultra-gran campo |
En pocas palabras
Se estudió el efecto de los agonistas del receptor de péptido similar al glucagón 1 en la retinopatía diabética y la angiogénesis. Los investigadores analizaron datos de pacientes con diabetes tipo 2 y realizaron experimentos en laboratorio. No se encontró asociación entre el uso de estos medicamentos y el empeoramiento de la retinopatía diabética.
Resumen divulgativo generado automáticamente a partir del resumen original; puede contener imprecisiones.
Resumen original
AIMS: Recent trials provide conflicting results on the association between glucagon-like peptide 1 receptor agonists (GLP-1RA) and diabetic retinopathy (DR). The aim of the AngioSafe type 2 diabetes (T2D) study was to determine the role of GLP-1RA in angiogenesis using clinical and preclinical models. METHODS: We performed two studies in humans. In study 1, we investigated the effect of GLP-1RA exposure from T2D diagnosis on the severity of DR, as diagnosed with retinal imaging (fundus photography). In study 2, a randomized 4-week trial, we assessed the effect of liraglutide on circulating hematopoietic progenitor cells (HPCs), and angio-miRNAs.We then studied the experimental effect of Exendin-4, on key steps of angiogenesis: in vitro on human endothelial cell proliferation, survival and three-dimensional vascular morphogenesis; and in vivo on ischemia-induced neovascularization of the retina in mice. RESULTS: In the cohort of 3154 T2D patients, 10% displayed severe DR. In multivariate analysis, sex, disease duration, glycated hemoglobin (HbA1c), micro- and macroangiopathy, insulin therapy and hypertension remained strongly associated with severe DR, while no association was found with GLP-1RA exposure (o 1.139 [0.800-1.622], P = .47). We further showed no effect of liraglutide on HPCs, and angio-miRNAs. In vitro, we demonstrated that exendin-4 had no effect on proliferation and survival of human endothelial cells, no effect on total length and number of capillaries. Finally, in vivo, we showed that exendin-4 did not exert any negative effect on retinal neovascularization. CONCLUSIONS: The AngioSafe T2D studies provide experimental and clinical data confirming no effect of GLP-1RA on angiogenesis and no association between GLP-1 exposure and severe DR.